Drug profile · INN
ranibizumab-eqrn
CIMERLI
ranibizumab-eqrn (CIMERLI) is a vascular endothelial growth factor a inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ranibizumab-eqrn
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ranibizumab-eqrn (CIMERLI) is a vascular endothelial growth factor a inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor A inhibitor
Primary target: Vascular endothelial growth factor A, long form
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ranibizumab-eqrn?
ranibizumab-eqrn (CIMERLI) is a vascular endothelial growth factor a inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ranibizumab-eqrn?
CIMERLI is a marketed brand name for ranibizumab-eqrn. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ranibizumab-eqrn?
ranibizumab-eqrn has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.